tiprankstipranks
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Holding BPMC?
Track your performance easily

Blueprint Medicines (BPMC) Ownership - Who Owns Blueprint Medicines?

544 Followers

Blueprint Medicines (BPMC) Ownership Overview

1.55%43.59%23.35%17.90%13.62%
23.35% Other Institutional Investors
17.90% ETFs
13.62% Public Companies and
Individual Investors
The ownership structure of Blueprint Medicines (BPMC) stock is a mix of institutional, retail, and individual investors. Approximately 84.84% of the company’s stock is owned by Institutional Investors, 1.55% is owned by Insiders, and 13.62% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 04, 2024
Fouad Namouni
President, R & D
xxxxxxxxxxxxx
$324500
Aug 07, 2024
xxxxxxxxxxxxx
$3905872
Jun 07, 2024
xxxxxxxxxxxxx
$420520
Jun 05, 2024
xxxxxxxxxxxxx
$259263

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$396547
Sep 30, 2024
xxxxxxxxxxxxx
$1570372
Sep 30, 2024
xxxxxxxxxxxxx
$31019875
Sep 30, 2024
xxxxxxxxxxxxx
$41955965

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
5,959,435Institution9.38%561,080,805
5,410,941Institution8.52%509,440,095
3,000,023Institution4.72%282,452,165
2,071,588Institution3.26%195,040,010
1,794,139Institution2.82%168,918,187
1,511,267Institution2.38%142,285,788
1,489,652Institution2.34%140,250,736
1,345,557Institution2.12%126,684,192
913,796Institution1.44%86,033,893
803,730Institution1.27%75,671,180

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
5,410,941Institution8.52%509,440,095
2,071,588Institution3.26%195,040,010
1,794,139Institution2.82%168,918,187
1,511,267Institution2.38%142,285,788
1,489,652Institution2.34%140,250,736
913,796Institution1.44%86,033,893
803,730Institution1.27%75,671,180
775,117Institution1.22%72,977,266
703,596Institution1.11%66,243,563
687,295Institution1.08%64,708,824

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,988,563Institution3.13%174,019,148
1,728,133Institution2.72%162,219,845
1,588,795Institution2.50%139,035,450
1,245,552Institution1.96%117,268,721
945,651Institution1.49%82,753,919
873,376Institution1.37%76,429,134
567,753Institution0.89%53,294,974
429,728Institution0.68%40,338,567
306,590Institution0.48%28,865,449
286,545Institution0.45%25,075,553

FAQ

Who Owns Blueprint Medicines (BPMC)?
According to the latest TipRanks data, approximately 23.35% of the company's stock is held by institutional investors, 1.55% is held by insiders, and 13.62% is held by retail investors.
    What percentage of Blueprint Medicines (BPMC) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 23.35% of Blueprint Medicines (BPMC) stock is held by institutional investors.
      What percentage of Blueprint Medicines (BPMC) stock is held by retail investors?
      According to the latest TipRanks data, approximately 13.62% of Blueprint Medicines (BPMC) stock is held by retail investors.
        Who owns the most shares of Blueprint Medicines (BPMC)?
        Vanguard owns the most shares of Blueprint Medicines (BPMC).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis